Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...

A defined jawline is the latest aesthetic ideal on the red carpet and beyond. Katie Rosseinsky explores how this became ...

Rapid fat loss from GLP-1 medications like Ozempic can lead to 'Ozempic face', characterized by hollow cheeks and sagging ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.